<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Suspected lung cancer (NG12 triggers) — DGRefHelp Drafts</title>
  <link rel="stylesheet" href="../assets/site.css" />
</head>
<body>
  <div class="container">
    <div class="header">
      <div class="brand">
        <h1><a href="../index.html">DGRefHelp drafts</a> / Suspected lung cancer (NG12 triggers)</h1>
        <div class="sub">Primary care triage: when to request an urgent CXR (within 2 weeks), what CXR findings should trigger a suspected cancer pathway referral, and what to do when symptoms persist despite a normal CXR (local-process sensitive).</div>
      </div>
      <div class="badges">
        <div class="badge">Mode: quick</div>
        <div class="badge">Last updated: 2026‑02‑10</div>
      </div>
    </div>

    <div class="grid">
      <div class="card">
        <div class="card-hd">
          <div class="tabs" data-tabs>
            <button class="tab" role="tab" data-tab="evidence" aria-selected="true">Evidence</button>
            <button class="tab" role="tab" data-tab="draft" aria-selected="false">DGRefHelp draft</button>
            <button class="tab" role="tab" data-tab="refs" aria-selected="false">References</button>
          </div>
          <div class="copybar">
            <button class="btn" data-copy-target="#draftText">Copy draft</button>
            <button class="btn" data-copy-target="#evidenceText">Copy evidence</button>
          </div>
        </div>

        <div class="card-bd">
          <div class="panel active" role="tabpanel" data-panel="evidence">
            <div id="evidenceText" class="section">
              <h3>Evidence summary (triangulated)</h3>

              <div class="callout ok">
                <strong>Key design points</strong>
                <ul>
                  <li>NICE NG12 separates lung cancer triage into: <strong>urgent CXR (within 2 weeks)</strong> for defined symptom combinations/signs, and <strong>suspected cancer pathway referral</strong> for people with imaging findings suggestive of malignancy (and other specified situations).</li>
                  <li>In primary care, the highest-yield action is to <strong>request the right test early</strong> (CXR), document <strong>smoking/asbestos exposure</strong>, and make sure there is a <strong>results-follow-up plan</strong> (safety-netting).</li>
                  <li>Scottish Right Decisions (NHS Highland) model provides a pragmatic operational layer: <strong>baseline blood tests</strong> (FBC/U&amp;E/LFT/calcium) and an expectation that referrals may be <strong>returned</strong> if required results are missing (timed pathway). It also highlights escalation when symptoms persist despite a normal CXR (local variation likely).</li>
                </ul>
              </div>

              <div class="callout warn">
                <strong>Local-process sensitivity</strong>
                <ul>
                  <li>Exact routing differs for D&amp;G: urgent CXR access route, who can order CT chest directly, and whether a suspected lung cancer pathway referral can be made with <strong>normal CXR</strong> but persistent concerning symptoms.</li>
                  <li>This page keeps the <strong>NICE triggers</strong> explicit, and puts routing uncertainties into a <strong>Local agreement needed</strong> checklist.</li>
                </ul>
              </div>

              <h4>Comparator sources used for the draft</h4>
              <ul>
                <li>NICE NG12: lung cancer (urgent CXR criteria) + mesothelioma criteria (asbestos/smoking modifies threshold).</li>
                <li>Right Decisions (NHS Highland): urgent suspected lung cancer quick reference (CXR triggers; suggested baseline bloods; referral acceptance/process notes; persistent symptoms with normal CXR).</li>
              </ul>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="draft">
            <div id="draftText" class="section">
              <h3>Suspected lung cancer — primary care triage (NG12 framing)</h3>

              <h4>Scope</h4>
              <ul>
                <li>This is a <strong>triage / referral trigger</strong> page (not a full diagnostic guideline).</li>
                <li>Adults in primary care. Use a lower threshold for urgent assessment if immunocompromised or systemically unwell.</li>
              </ul>

              <h4>Immediate red flags (send same day / ED)</h4>
              <ul>
                <li>Severe breathlessness/hypoxia, haemodynamic instability, sepsis, or large-volume/ongoing haemoptysis.</li>
                <li>Concern for <strong>PE</strong> or <strong>ACS</strong> with instability.</li>
              </ul>

              <h4>Step 1 — identify people who need an urgent CXR (within 2 weeks)</h4>
              <ul>
                <li><strong>NICE NG12: offer urgent CXR</strong> (within 2 weeks) to assess for lung cancer in people <strong>aged ≥40</strong> if they have:
                  <ul>
                    <li><strong>2 or more</strong> of: unexplained <strong>cough</strong>, <strong>fatigue</strong>, <strong>shortness of breath</strong>, <strong>chest pain</strong>, <strong>weight loss</strong>, <strong>appetite loss</strong>, OR</li>
                    <li>have <strong>ever smoked</strong> and have <strong>1 or more</strong> of the above unexplained symptoms.</li>
                  </ul>
                </li>
                <li><strong>NICE NG12: consider urgent CXR</strong> (within 2 weeks) in people aged ≥40 with any of:
                  <ul>
                    <li>persistent or recurrent chest infection</li>
                    <li>finger clubbing</li>
                    <li>supraclavicular lymphadenopathy or persistent cervical lymphadenopathy</li>
                    <li>chest signs consistent with lung cancer</li>
                    <li>thrombocytosis</li>
                  </ul>
                </li>
                <li>Also see related pages:
                  <ul>
                    <li><a href="./haemoptysis.html">Haemoptysis</a></li>
                    <li><a href="./chronic-cough.html">Chronic cough</a></li>
                    <li><a href="./pleural-effusion.html">Pleural effusion</a> (effusion is a key imaging trigger)</li>
                  </ul>
                </li>
              </ul>

              <h4>Step 2 — what to do with the CXR result</h4>
              <ul>
                <li><strong>CXR suspicious for lung/pleural malignancy</strong> (e.g. mass, pleural mass, pleural effusion, slowly resolving consolidation) → <strong>suspected lung cancer pathway referral</strong> (urgent) per local process.</li>
                <li><strong>CXR shows consolidation</strong> and infection is treated:
                  <ul>
                    <li>ensure a <strong>repeat CXR within ~6 weeks</strong> if symptoms/signs persist or higher malignancy risk (local practice; see local agreement).</li>
                  </ul>
                </li>
                <li><strong>Normal CXR but ongoing concern</strong>:
                  <ul>
                    <li>do not dismiss persistent red-flag symptoms; consider escalation (CT chest / respiratory review / suspected cancer route) per local process.</li>
                    <li>Right Decisions (NHS Highland) model uses a trigger of <strong>&gt;6 weeks persistent symptoms</strong> (including persistent haemoptysis in smokers/ex-smokers &gt;40) despite normal CXR, but local pathways vary.</li>
                  </ul>
                </li>
              </ul>

              <h4>What to include in requests/referrals (minimum useful data)</h4>
              <ul>
                <li>Symptoms (onset/duration) + red flags (weight loss, haemoptysis, chest pain, breathlessness).</li>
                <li><strong>Smoking history</strong> (current/ex/never; pack-years if available) and <strong>asbestos exposure</strong>.</li>
                <li>Observations if symptomatic: HR, BP, RR, Temp, <strong>SpO2 on air</strong>.</li>
                <li>Examination findings (focal chest signs; lymphadenopathy; clubbing).</li>
                <li>Relevant comorbidities (COPD, ILD, immunosuppression) and anticoagulant/antiplatelet use.</li>
                <li>Results attached where required locally (CXR report/images; baseline bloods).</li>
              </ul>

              <h4>Safety-netting</h4>
              <ul>
                <li>Ensure the patient knows who will contact them with results (and when), and when/how to re-present if symptoms worsen.</li>
                <li>Escalate urgently if: new/worsening breathlessness, haemoptysis, chest pain, systemic deterioration.</li>
              </ul>

              <h4>Local agreement needed (D&amp;G)</h4>
              <ul>
                <li><label><input type="checkbox" /> What is the local route for <strong>urgent CXR (within 2 weeks)</strong> for NG12 lung/pleural triggers?</label></li>
                <li><label><input type="checkbox" /> What CXR findings trigger a <strong>suspected lung cancer pathway</strong> referral locally (mass/effusion/pleural abnormality/slowly resolving consolidation)?</label></li>
                <li><label><input type="checkbox" /> Are <strong>baseline bloods</strong> required for referral acceptance (e.g. FBC/U&amp;E/LFT/calcium; any others)?</label></li>
                <li><label><input type="checkbox" /> If CXR is normal but symptoms persist with cancer concern: local expectation for <strong>CT chest</strong> (direct access?) vs respiratory clinic vs 2WW referral.</label></li>
                <li><label><input type="checkbox" /> What is the local policy for <strong>repeat CXR after pneumonia/consolidation</strong> (timing; who requests; in which risk groups)?</label></li>
                <li><label><input type="checkbox" /> Mesothelioma: if asbestos exposure + symptoms, confirm local threshold/routing (NG12 modifies urgency based on smoking/asbestos).</label></li>
              </ul>

              <div class="callout warn">
                <strong>Reminder</strong>
                <div class="small">A normal CXR does not exclude lung cancer. If symptoms persist or evolve, re-assess and escalate (local route).</div>
              </div>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="refs">
            <div class="section">
              <h3>References</h3>
              <ul>
                <li>NICE. <em>Suspected cancer: recognition and referral (NG12)</em>. Recommendations organised by site of cancer (lung and pleural cancers). Updated/amended (see NICE page). Accessed 2026‑02‑10. https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer</li>
                <li>Right Decisions (NHS Highland). <em>Urgent suspected Lung Cancer (Guidelines)</em>. Accessed 2026‑02‑10. https://www.rightdecisions.scot.nhs.uk/tam-treatments-and-medicines-nhs-highland/adult-therapeutic-guidelines/respiratory/urgent-suspected-lung-cancer-guidelines/</li>
              </ul>
            </div>
          </div>

        </div>
      </div>
    </div>
  </div>

  <script src="../assets/site.js"></script>
</body>
</html>
